US FDA Employs Familiar Strategy In Ending Novo’s Wegovy, Ozempic Shortage

A declaratory order removing semaglutide from the FDA shortages list duplicates much of the language in a December decision still in litigation that declared Eli Lilly’s tirzepatide products Mounjaro and Zepbound were no longer in shortage.